Kim Kelderman - Bio Techne Pres Genomics
| T1CH34 Stock | 13.08 0.36 2.68% |
Executive
Kim Kelderman is Pres Genomics of Bio Techne
| Age | 56 |
| Phone | 612 379 8854 |
| Web | https://www.bio-techne.com |
Kim Kelderman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Kim Kelderman against Bio Techne stock is an integral part of due diligence when investing in Bio Techne. Kim Kelderman insider activity provides valuable insight into whether Bio Techne is net buyers or sellers over its current business cycle. Note, Bio Techne insiders must abide by specific rules, including filing SEC forms every time they buy or sell Bio Techne'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Kim Kelderman over two months ago Acquisition by Kim Kelderman of 1492 shares of Bio Techne at 66.97 subject to Rule 16b-3 | ||
Kim Kelderman over three months ago Acquisition by Kim Kelderman of 1492 shares of Bio Techne at 66.97 subject to Rule 16b-3 |
Bio Techne Management Efficiency
The company has return on total asset (ROA) of 0.0771 % which means that it generated a profit of $0.0771 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1483 %, meaning that it generated $0.1483 on every $100 dollars invested by stockholders. Bio Techne's management efficiency ratios could be used to measure how well Bio Techne manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | EXECUTIVE Age | ||
| Cassio Silva | Companhia Paranaense de | 45 | |
| Eduardo Barbosa | Companhia Paranaense de | 41 | |
| Jorge Jnior | Companhia Paranaense de | 71 | |
| Henrique Neto | Companhia Paranaense de | 70 | |
| Hemerson Souza | Fras le SA | N/A | |
| David Campos | Companhia Paranaense de | 54 | |
| Anderson Pontalti | Fras le SA | N/A | |
| Ana Feller | Companhia Paranaense de | 46 | |
| Vicente Neto | Companhia Paranaense de | 40 | |
Management Performance
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0771 |
Bio Techne Leadership Team
Elected by the shareholders, the Bio Techne's board of directors comprises two types of representatives: Bio Techne inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio Techne's management team and ensure that shareholders' interests are well served. Bio Techne's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio Techne's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kim Kelderman, Pres Genomics | ||
| David Clair, Sr Devel | ||
| Robert Gavin, VP Devel | ||
| Luca Cicchetti, Managing Director | ||
| Brenda JD, Gen VP | ||
| William Geist, Pres Segment | ||
| James Hippel, Exec CFO | ||
| Charles Kummeth, Pres CEO | ||
| Brenda Everson, VP Officer | ||
| Gerry Andros, VP Marketing |
Bio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bio Techne a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | |||
| Return On Asset | 0.0771 | |||
| Profit Margin | 0.23 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 73.29 B | |||
| Shares Outstanding | 4.72 B | |||
| Price To Book | 7.19 X | |||
| Price To Sales | 65.05 X | |||
| Revenue | 1.11 B | |||
| Gross Profit | 758.09 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Bio Stock
Bio Techne financial ratios help investors to determine whether Bio Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bio with respect to the benefits of owning Bio Techne security.